… able to get treatment with a life-extending drug which has been … & Johnson's Zytiga brand and generics – to be … abiraterone to include first-line treatment of hormone-sensitive prostate … their cancer coming back after treatment and also halved their …

… FDA-approved treatment, a therapy developed by biotechnology … medications. Rare Disease Approvals —Agios’s twice-daily pill … . —The FDA approved Arrowhead Pharmaceuticals’ Redemplo for … drug Zytiga. The FDA first approved Akeega in 2023 as a treatment …

… pill remained a major advantage over the IV-administered Rybrevant. The FDA … multiple myeloma treatment Darzalex and prostate cancer drug Erleada. … the clinical-stage biotech Halda Therapeutics for … strong presence with drugs like Zytiga, Erleada and Akeega …

The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of … multicenter, open-label, randomized TRITON3 trial served as the confirmatory study … pathway inhibitor (such as abiraterone [Zytiga], enzalutamide [Xtandi], or apalutamide [ …

… immunotherapies, targeted treatments and personalized vaccines have broadened … and earlier intervention. Pharmaceutical companies are responding … oncology therapies. Smaller biotech firms continue to … strong presence with drugs like Zytiga, Erleada and …

The FDA has approved rucaparib (Rubraca; Pharmaand GmbH) for the treatment of … TRITON3 trial were published in The New England Journal of Medicine.1 … Pharma, Pfizer], abiraterone acetate [Zytiga; Janssen Biotech]), or docetaxel. Randomization was stratified …

… randomized, phase 3 trial included patients with … such as abiraterone acetate (Zytiga) or enzalutamide (Xtandi; … The most frequent treatment-emergent adverse effects ( … 47;www.fda.gov/drugs/;resources-information-approved-drugs/fda-grants-accelerated …

… treatment with a fresh FDA approval, making it the first precision medicine … androgen-directed prostate cancer med Zytiga (abiraterone acetate) and the … J&J’s Amplitude trial is an ongoing phase 3 … wider struggles of the PARP drug class to extend beyond …

… an assistant professor of medicine in the division of … of the TRIPLE-SWITCH trial, a phase 3 … multiple trials—including TITAN (apalutamide [Erleada]), LATITUDE (abiraterone acetate [Zytiga]), … , Sokolova argues that treatment intensification is warranted before …

… Arvinas Therapeutics, a biotech company developing drugs based on a … pairs the active pharmaceutical ingredient in Zytiga with niraparib, a … executive vice president, innovative medicine, R&D at … longer respond to standard treatments using a novel mechanism …